Characteristics of ATLL
Clinical characteristic . | No. (n = 135) . | % . |
---|---|---|
Age, y, median (range) | 67 (35-90) | — |
Sex, male/female | 76/59 | 56/44 |
ECOG PS, 2-4 | 43/132 | 33 |
Shimoyama classification | ||
Smoldering type | 2/111 | 2 |
Acute type | 56/111 | 51 |
Lymphoma type | 53/111 | 48 |
B symptom | 42/130 | 32 |
Elevated LDH | 77 | 57 |
Hypercalcemia | 21 | 16 |
Elevated CRP | 80/132 | 61 |
Ann Arbor stage, III or IV | 113/134 | 84 |
Peripheral blood involvement | 70/132 | 53 |
Bone marrow involvement | 30/106 | 28 |
Skin lesion | 23/134 | 17 |
WBC, ×109/L, median (range) | 6.6 (1.2-97.1) | — |
Hemoglobin, g/dL, median (range) | 12.9 (6.3-18.6) | — |
Platelets, ×109/L, median (range) | 213 (19-840) | — |
IPI, high-intermediate or more | 78/129 | 61 |
JCOG-PI, high | 52/132 | 39 |
Treatment | ||
Chemotherapy | 117/133 | 88 |
Radiation | 14/131 | 11 |
Transplantation | 19/131 | 15 |
No chemotherapy or radiotherapy | 13/133 | 10 |
CR or CR(u) | 35/116 | 30 |
Clinical characteristic . | No. (n = 135) . | % . |
---|---|---|
Age, y, median (range) | 67 (35-90) | — |
Sex, male/female | 76/59 | 56/44 |
ECOG PS, 2-4 | 43/132 | 33 |
Shimoyama classification | ||
Smoldering type | 2/111 | 2 |
Acute type | 56/111 | 51 |
Lymphoma type | 53/111 | 48 |
B symptom | 42/130 | 32 |
Elevated LDH | 77 | 57 |
Hypercalcemia | 21 | 16 |
Elevated CRP | 80/132 | 61 |
Ann Arbor stage, III or IV | 113/134 | 84 |
Peripheral blood involvement | 70/132 | 53 |
Bone marrow involvement | 30/106 | 28 |
Skin lesion | 23/134 | 17 |
WBC, ×109/L, median (range) | 6.6 (1.2-97.1) | — |
Hemoglobin, g/dL, median (range) | 12.9 (6.3-18.6) | — |
Platelets, ×109/L, median (range) | 213 (19-840) | — |
IPI, high-intermediate or more | 78/129 | 61 |
JCOG-PI, high | 52/132 | 39 |
Treatment | ||
Chemotherapy | 117/133 | 88 |
Radiation | 14/131 | 11 |
Transplantation | 19/131 | 15 |
No chemotherapy or radiotherapy | 13/133 | 10 |
CR or CR(u) | 35/116 | 30 |
Pathological characteristics . | No. (n = 135) . | % . |
---|---|---|
Morphological classification | ||
Small cell variant | 3 | 2 |
Medium cell variant | 28 | 21 |
Large cell variant | 57 | 42 |
Hodgkin like variant | 2 | 2 |
Anaplastic variant | 9 | 7 |
Pleomorphic variant | 36 | 27 |
IHC | ||
nPD-L1 positive | 10 | 7 |
nPD-L1 negative | 125 | 93 |
mPD-L1 positive | 79 | 59 |
PD-L1 positive | 46 | 34 |
Neoplastic cells | ||
PD-1, positive | 25 | 19 |
CD30, positive | 36 | 27 |
FoxP3, positive | 35 | 26 |
CCR4, positive | 126 | 93 |
PD-1-positive TIL, counts/HPF, average (range) | 2.4 (0-38.4) | — |
Pathological characteristics . | No. (n = 135) . | % . |
---|---|---|
Morphological classification | ||
Small cell variant | 3 | 2 |
Medium cell variant | 28 | 21 |
Large cell variant | 57 | 42 |
Hodgkin like variant | 2 | 2 |
Anaplastic variant | 9 | 7 |
Pleomorphic variant | 36 | 27 |
IHC | ||
nPD-L1 positive | 10 | 7 |
nPD-L1 negative | 125 | 93 |
mPD-L1 positive | 79 | 59 |
PD-L1 positive | 46 | 34 |
Neoplastic cells | ||
PD-1, positive | 25 | 19 |
CD30, positive | 36 | 27 |
FoxP3, positive | 35 | 26 |
CCR4, positive | 126 | 93 |
PD-1-positive TIL, counts/HPF, average (range) | 2.4 (0-38.4) | — |
CRP, C-reactive protein; CR, complete response/remission; CR(u), uncertain complete response/remission; ECOG PS, Eastern Cooperative Oncology Group performance status; IPI, international prognostic index; LDH, lactate dehydrogenase; WBC, white blood cell.